Biotech VC Funds

Climentum Capital is a Copenhagen-based venture capital firm launched in 2022, focused on investing in early-stage European climate tech startups that are driving significant CO2 reductions. The firm is particularly known for its commitment to "hard-tech" solutions—innovations that combine hardware and deep technology to address major industrial challenges. Climentum Capital invests primarily in Seed and Series A rounds, with typical investments ranging from €1 million to €5 million. The firm's investment thesis centers on six key sectors: Next Generation Renewables, Food & Agriculture, Industry & Manufacturing, Buildings & Architecture, Transportation & Mobility, and Waste & Materials. With offices in Copenhagen, Berlin, and Stockholm, Climentum has a strong presence in the Nordics and the DACH region, areas known for their leadership in sustainability and industrial innovation. Climentum Capital operates as an Article 9 fund, which under the EU's Sustainable Finance Disclosure Regulation (SFDR) means that all of its investments must have a measurable positive impact on the environment. The firm uses a dual carry structure, linking financial returns with CO2 emissions reduction goals to ensure that both economic and environmental objectives are met. In 2024, Climentum announced plans to launch a second fund, targeting €100 million to continue its mission of supporting high-impact climate tech startups across Europe. The firm has already made significant investments in companies like Qvantum and Novatron Fusion, which are developing next-generation heat pumps and fusion reactors, respectively​.

Closed Loop Partners is a New York-based investment firm dedicated to advancing the circular economy through venture capital, growth equity, private equity, and catalytic capital investments. The firm focuses on transforming linear supply chains into circular ones by investing in innovations across material science, robotics, agritech, sustainable consumer products, and advanced recycling technologies. Established in 2014, Closed Loop Partners has made significant strides in promoting sustainability and reducing waste. The firm manages several funds, including the Closed Loop Ventures Group, which targets early-stage companies, and the Closed Loop Leadership Fund, a private equity fund focused on acquiring and building businesses that enhance circular supply chains. Key sectors of investment include plastics and packaging, fashion, food and agriculture, and technology. The firm’s portfolio boasts companies like AMP Robotics, Algramo, and Evrnu, which are at the forefront of sustainable innovations. Closed Loop Partners emphasizes the importance of aligning economic growth with environmental impact, having kept millions of tons of materials in circulation and avoided significant greenhouse gas emissions through its investments​. Overall, Closed Loop Partners leverages its extensive network and expertise to support the development and scaling of solutions that contribute to a resilient and waste-free economy.

CM Venture Capital, headquartered in Shanghai, China, is an early and growth-stage venture capital firm focusing on investing in hard-tech innovations that drive significant industrial transformations. Founded in 2010, the firm is committed to supporting startups that are developing advanced materials, digital industrial solutions, and technologies for energy and environmental sustainability. CM Venture's investment strategy is centered on predicting future trends and selecting startups poised to become industry leaders. They emphasize deep technological expertise and work closely with portfolio companies to provide strategic guidance and mentorship. Their notable investments include Econic, a UK-based company developing catalysts to incorporate CO2 into materials, and NovoNutrients, a US-based startup producing food and feed from CO2​. The firm collaborates with corporate venture capital arms of multinational companies such as GE, Samsung, and BASF, leveraging their extensive networks and industry experience to help startups scale effectively. Their portfolio spans across various sectors, including 5G, hydrogen energy, automation, and sustainable materials​.

Coatue Management is a top-tier venture capital firm renowned for its investments in transformative technology companies. With notable investments in industry giants like ByteDance, Niantic, Airtable, and DoorDash, Coatue's portfolio is diverse and impressive. They focus primarily on sectors such as fintech, enterprise software, healthcare, and AI, investing globally with a strong presence in the U.S., Europe, and Asia. Coatue operates across multiple investment stages, from early-stage venture capital to growth equity and public markets. Their strategy involves deploying significant capital swiftly to capture emerging opportunities, with investments ranging from $10 million to over $100 million. They are known for their agility and ability to provide strategic support and resources to their portfolio companies. Led by founder Philippe Laffont and his brother Thomas Laffont, the team includes heavy-hitters like Dan Rose, a former VP at Facebook, and enterprise investment experts Jade Lai and Nina Gerson. They have offices in New York, Menlo Park, Los Angeles, London, and Hong Kong, reflecting their global reach. Coatue prefers startups to approach them through their network, valuing introductions that demonstrate a strong product-market fit and the potential for significant impact. The firm is highly active, often leading funding rounds and providing ongoing support to help their companies scale​.

CoFound Partners is a New York-based venture capital firm that focuses on helping founders build scalable sales processes, primarily investing in early-stage B2B software companies. The fund, led by Jordan Wan, emphasizes GTM (go-to-market) strategies and provides hands-on support to founders, leveraging its expertise and extensive network to help startups secure key early customers and hire critical talent. CoFound typically makes 5-7 high-conviction investments per year, with an initial check size between $250k-$500k, and reserves half of its fund for follow-on rounds. Their portfolio includes notable companies like ChartHop, Cue Health, and Plaid, with a focus on sectors such as enterprise SaaS, digital health, fintech, and climate tech. While most of their investments are U.S.-based, they occasionally invest in companies from Canada, Western Europe, and Israel. CoFound's approach is highly collaborative, often co-investing alongside top-tier firms like Andreessen Horowitz and Index Ventures. For startups, CoFound is a first-check investor that brings a wealth of operational expertise, especially in sales strategy and talent acquisition. Founders working with CoFound receive not only financial backing but also mentorship in building a repeatable sales motion, which has proven valuable in scaling companies like Gentem and Reclaim.ai.

CofounderZone is a Warsaw-based early-stage venture capital fund focusing on tech startups across Central and Eastern Europe. Its portfolio includes companies in AI, IoT, software, and automation, with a preference for B2B and B2G models. Notable investments include EcoBean, Foodsi, and Aleet. CofounderZone typically targets pre-seed and seed-stage startups, providing both capital and strategic support to propel growth. The firm is particularly active in sectors like clean tech, digital health, and fintech. CofounderZone operates with a unique model that combines angel investors and established entrepreneurs. This network offers startups deep expertise in business strategy and execution. The fund’s investment strategy emphasizes minority stakes, and it has been involved in some key rounds, including Aleet's $1.25M pre-Series A. Founders Tomasz Goliński, Ph.D., and Michał Sioda, CFA, lead the fund’s operations with extensive backgrounds in finance, corporate restructuring, and technology ventures. Their focus is on hands-on partnerships, with a strong interest in innovation-driven solutions. For startups looking to connect, CofounderZone values personalized approaches that highlight the startup’s potential for scalability and technological innovation. They are a dynamic presence in the region, steadily building a diverse investment portfolio.

COI Partners, founded in 2001, is a growth equity investor based in Zurich, Switzerland, with additional offices in Frankfurt and Berlin. They focus on high-growth companies in the DACH region (Germany, Austria, and Switzerland), investing primarily in the IT and software, consumer and retail, life sciences, and industrial sectors. Their investment strategy emphasizes deal-by-deal and fund investments, typically ranging from €15 million to €30 million per company. COI Partners has a strong track record of 110 investments and 40 successful exits, including notable companies like Grover, Freaks 4U Gaming, and Mister Spex. They value a close partnership with entrepreneurs, providing not just capital but also strategic support and leveraging their extensive network of industry experts. The fund aims to fill the growth capital gap in the DACH region, offering local startups the opportunity to scale without relying heavily on foreign investors. Their latest initiative, the €120 million COIP DACH Growth II fund, reinforces their commitment to supporting growth-stage companies in the region. Key team members include Nicolai von Engelhardt and Farsin Yadegardjam, who bring extensive experience in investment and portfolio management. COI Partners’ approach is rooted in entrepreneurial spirit, making them a preferred partner for startups ready to scale and achieve significant growth.

Coinbase Ventures, the venture capital arm of Coinbase, focuses on investing in early-stage cryptocurrency and blockchain startups. Since its inception, the firm has made significant investments in over 250 companies, positioning itself as a leading player in the crypto investment space. Notable investments include Compound, a decentralized finance (DeFi) protocol; OpenSea, the largest marketplace for NFTs; and BlockFi, a platform for crypto-backed loans. The firm’s portfolio is diversified across various categories, with prominent investments in DeFi, centralized finance (CeFi), web3 infrastructure, and NFTs​. Coinbase Ventures typically invests in seed and early-stage rounds, often partnering with other leading venture capital firms to support their portfolio companies' growth and development. Their strategic focus areas include blockchain infrastructure, decentralized applications, and financial services, aiming to advance the broader adoption of crypto technologies. The firm operates globally, with investments spanning North America, Europe, and Asia. This international reach allows them to tap into diverse markets and support a wide range of innovative projects. For startups looking to secure investment from Coinbase Ventures, it is crucial to demonstrate strong technical innovation, a clear market need, and the potential for significant impact within the crypto ecosystem. Engaging with Coinbase Ventures through their network or strategic introductions can enhance the likelihood of securing funding

Collaborative Fund, founded in 2010 by Craig Shapiro, is a venture capital firm focused on supporting entrepreneurs and ideas that push the world forward. The firm primarily invests in early-stage companies across various sectors, including next-gen consumer products, climate solutions, industrial transformation, food innovation, and precision health. Some of their notable investments include Beyond Meat, Lyft, Impossible Foods, and Sweetgreen. The firm recently raised $200 million for two new funds: Collaborative V and Collaborative Growth. Collaborative V focuses on early-stage investments, while Collaborative Growth targets more established startups looking to scale​. Collaborative Fund's investment philosophy emphasizes sustainability, social impact, and innovative solutions that address global challenges.

Colle Capital is a global, early-stage venture fund known for its opportunistic approach. Led by founder Victoria Grace, Colle focuses on sectors such as logistics, fintech, healthcare, and advanced technology, often backing companies with strong data-driven models. Key investments include notable names like Maven Clinic, Hyliion, LiquidPiston, and MarketMuse, highlighting its diverse portfolio from digital health to AI. Based in New York, the fund does not limit itself geographically, investing across the U.S., Europe, and emerging markets. Colle Capital primarily targets seed to Series A stages, with a flexible strategy that includes both leading and co-investing in rounds. They’re known for writing checks ranging from $1M to $5M depending on the company’s potential and sector. Victoria Grace, with her background in private equity and investment banking, emphasizes supporting innovative startups with scalable impact. Colle looks for strong founders and products with a clear path to commercialization. Startups seeking to pitch should focus on data integrity, market scalability, and strategic vision, as these are critical criteria for the fund. Colle remains active in sectors with strong network effects and emerging technologies.

Colopl Next is a venture capital arm of Colopl Inc., a prominent Japanese gaming company, founded in 2015. Colopl Next focuses on investing in startups and publicly listed companies, with a strong emphasis on emerging technologies, B2C services, and the entertainment sector. The firm leverages its extensive knowledge in these areas to support young entrepreneurs and innovative companies globally. The fund's industry focus includes virtual reality (VR), augmented reality (AR), artificial intelligence (AI), blockchain, and other cutting-edge technologies. Notable investments include companies like Flitto and Kaizen Platform, which have successfully gone public. Colopl Next also has a robust presence in sectors like lifestyle services, health, and media content, supporting ventures that align with the theme of "Entertainment in Real Life". Geographically, Colopl Next primarily operates from Tokyo, Japan, but it also invests in international startups, including those in Korea and Southeast Asia. Their investment strategy includes a range of funds, such as the Next Unicorn Fund and several others dedicated to different stages and focuses, from seed investments to more mature stages. Colopl Next is known for its hands-on support approach, providing extensive resources through a network of over 200 portfolio companies, numerous advisors, and experts. This support is augmented by the diverse backgrounds of its team members, including former investment managers and successful entrepreneurs. The leadership team at Colopl Next includes key figures like Naruatsu Baba and Sehong Jang, who bring substantial experience and strategic vision to the firm. Startups seeking investment from Colopl Next are encouraged to showcase innovative technologies and robust growth potential​.

Commonweal Ventures is an early-stage venture capital firm focusing on companies at the intersection of technology and public policy. The firm targets sectors such as clean energy, healthcare, financial services, transportation, and infrastructure, aiming to support startups positioned to capitalize on shifts in government regulations and public investments. Their typical investment ranges from $250K to $2M, participating in pre-seed through Series A rounds, often leading or co-leading. Founded by Nate Loewentheil, a former Obama White House official with extensive experience in infrastructure and technology, Commonweal backs startups with the potential to drive large-scale societal improvements. Notable portfolio companies include firms advancing sustainability and urban revitalization efforts​. The firm is deeply involved in helping companies navigate the evolving policy landscape to unlock growth opportunities. Their team consists of key figures from both the public and private sectors, including General Partner Ron Bloom, a former senior advisor in the U.S. government. This diverse leadership enables Commonweal to provide not only capital but also strategic guidance in areas heavily influenced by regulation.

Compound is a thesis-driven, research-centric investment firm that focuses on early-stage investments across deeply technical and science-driven areas. The firm is dedicated to accelerating the futures envisioned by its founders, helping them solve complex technical problems, communicate breakthroughs, and scale commercialization efforts. Founded by Michael Dempsey, Compound has a diverse team of investors, researchers, and operators with extensive domain expertise. Notable team members include General Partner David Hirsch and Venture Partners like Celeste Holz-Schietinger, who has a background in biology and was instrumental in creating plant-based meat products at Impossible Foods. Compound's portfolio is broad, encompassing sectors like AI/ML, robotics, healthcare, biology, and crypto. Notable investments include companies such as Deepgram, Hyphen, Arbitrum, and Dapper Labs. The firm emphasizes a hands-on approach and leverages its network and prior experiences to support the growth and success of its portfolio companies.

Congruent Ventures is a leading early-stage venture capital firm focusing on climate tech and sustainability. Based in San Francisco, they have a robust portfolio featuring notable startups like AMP Robotics, Span.io, and Meati Foods. Since its inception in 2016, Congruent has specialized in North American investments, particularly at the pre-seed to Series A stages, across sectors including food, energy, and advanced materials. With $1 billion in assets under management, Congruent typically leads two-thirds of its investments and is often the first institutional investor in 80% of its portfolio companies. Their average check size varies but primarily targets early-stage funding needs. Recently, they've been highly active, closing their $275 million Fund III to continue backing transformative climate solutions. The team, led by co-founders Abe Yokell and Josh Posamentier, along with partners like Jackie Kossmann and Tanuj Dutta, combines deep expertise in climate tech and venture capital. They emphasize a hands-on approach, working closely with founders from inception to scaling. For startups seeking investment, Congruent Ventures values direct approaches via email and emphasizes alignment with their mission of tackling climate change through innovative technologies. They prefer entrepreneurs who can demonstrate substantial impact potential and readiness for early-stage investment​.

Connect Ventures, established in 2012 and based in London, is a venture capital firm that focuses on early-stage investments in Europe. The firm is particularly interested in product-led founders and companies that leverage emerging technologies to create or disrupt large markets. Connect Ventures has a diverse portfolio, including notable investments like Citymapper, an urban navigation app; Typeform, an online survey platform; and Curve, a fintech company that consolidates multiple bank cards into one. Recent investments also include Metomic, which helps businesses detect and control sensitive data in cloud applications, and Sprinque, a B2B checkout solution with embedded trade finance​. The firm typically invests in seed and Series A rounds, with initial check sizes ranging from €500,000 to €3 million. Connect Ventures aims to provide not just capital but also strategic guidance and support, helping startups scale and succeed in competitive markets. They are known for their hands-on approach and commitment to partnering with founders through every stage of growth.

Connecticut Innovations (CI) is Connecticut’s strategic venture capital arm, dedicated to supporting the state's innovative and high-growth companies. Founded in 1989, CI invests across various industries, including biotech, IT, cleantech, and advanced manufacturing. They manage several funds, including the $50 million Future Fund, which targets early-stage, tech-enabled startups with diverse teams, emphasizing underrepresented founders. Investment sizes range from $250,000 to $1.5 million. Notable investments from CI’s diverse portfolio include companies like Athletic Brewing, Budderfly, and Veradermics. The firm’s commitment to diversity is further highlighted by the ClimateTech Fund, a $100 million initiative to support climate and adaptation technology ventures aimed at decarbonization and job creation in Connecticut​. Leading the team is CEO Matt McCooe, who brings over 25 years of venture capital experience. Key team members also include Alison Malloy, Managing Director of Investments, who co-manages the Future Fund, and Konstantine Drakonakis, Managing Director for the ClimateTech Fund. Connecticut Innovations prioritizes companies that are willing to maintain a presence in Connecticut, leveraging co-investment opportunities to maximize growth potential and support from a network of experienced partners and advisors. Their holistic approach involves strategic guidance, financial backing, and extensive networking opportunities to ensure portfolio companies thrive

Conscience VC is an early-stage venture capital firm that focuses on funding innovative startups aiming to make a positive impact on the world. Founded in 2020 by Ariana Thacker, the firm is headquartered in Austin, Texas. Conscience VC invests primarily in the intersection of consumer and science, with a particular emphasis on sectors such as biotechnology, digital health, clean tech, and other socially responsible industries. The firm is notable for its commitment to diversity and inclusion, with over 50% of its portfolio companies led by female and diverse founders. Ariana Thacker, the driving force behind Conscience VC, is a passionate advocate for underrepresented groups in the venture capital space, leveraging her technical background in chemical engineering to support groundbreaking companies. Conscience VC has made 14 investments to date, including companies like Aqua Cultured Foods and Somite Therapeutics, and continues to prioritize Environmental, Social, and Governance (ESG) principles in its investment strategy.

CNB Capital is a Vienna-based venture capital firm that focuses on early-stage investments, particularly in high-tech B2B companies demonstrating early customer traction. The firm primarily invests in the DACH region (Germany, Austria, Switzerland) and surrounding European markets. With typical investments ranging from €1.5M to €3M, CNB targets sectors like industrial automation, information technology, and advanced manufacturing, seeking scalable solutions with strong differentiation. The firm’s investment strategy emphasizes long-term partnerships with startups, providing not only capital but also strategic support in areas such as sales, marketing, and corporate development. CNB Capital operates with an evergreen fund model, allowing it to maintain a long-term view on growth and sustainability rather than being constrained by traditional fund cycles. Their team, led by Philipp Thurn und Taxis, is particularly active in fostering technological advancements that can disrupt industries and create substantial market impact. CNB has built a portfolio that includes companies like Hydrogrid, Neural Concept, and Fruitcore Robotics. These investments highlight their focus on innovative, tech-driven solutions capable of transforming traditional industries. Startups looking to collaborate with CNB Capital are often those with a clear unique selling proposition and the potential for high growth in niche markets.

Continental Grain Company, also known as Conti, is a privately-owned global investor with a rich history spanning over 200 years in the food and agribusiness sectors. Founded in 1813, the company operates across North America, Latin America, Asia, and Europe, making investments that cover the entire food supply chain, from production to processing and distribution. Conti's investment strategy focuses on leveraging its deep industry expertise, flexible capital, and extensive partnership network to build businesses that create long-term value. This includes backing early-stage growth companies that use cutting-edge technology to innovate within the agrifood space. Notable investments in their portfolio include Pivot Bio, Brightseed, and Bushel, which are leading advancements in ag biotech, digital infrastructure, and alternative proteins. In recent years, Continental Grain has expanded its footprint through significant acquisitions and partnerships. For example, the company formed a joint venture with Cargill to acquire Sanderson Farms, creating Wayne-Sanderson Farms, a major U.S. poultry business. This move underscores Conti's commitment to scaling its operations and maintaining a strong presence in the food production sector​.

Coronis Medical Ventures is a venture capital firm based in Milpitas, California, focusing on early-stage investments in the medical device sector. Established in 2006, it operates as both a seed fund and a business accelerator, supporting startups in fields such as cardiovascular, neurovascular, and minimally invasive therapeutic devices. Coronis is known for providing capital, prototyping support, and hands-on development to help medical companies bring their innovations to market. With notable investments in companies like Varix Medical and VasoNova, Coronis typically leads at the seed stage, helping startups achieve proof of concept before seeking larger follow-on funding for commercialization. The firm's leadership includes veteran medical device entrepreneurs, including Mark Klopp and Roger Stern, who bring extensive industry experience​. Coronis has made a significant impact by combining venture funding with practical guidance and strategic leadership, positioning itself as a key player in medical technology innovation​.

Correlation Ventures, founded in 2006 and based in San Francisco, leverages predictive analytics to make investment decisions, positioning itself as a unique player in the venture capital landscape. With over 519 investments, the firm has backed notable companies such as IonQ, MosaicML, Imperfect Foods, and Personal Capital. Their innovative approach allows them to make rapid investment decisions, typically within two weeks, without traditional due diligence, making them a preferred co-investor for many lead venture capitalists​​. Correlation Ventures typically invests between $1 million and $4 million, focusing on diverse sectors including AI, fintech, healthcare, and consumer products. Their portfolio is characterized by a high level of diversification, including early investments in companies that have achieved significant exits such as Synthorx, which was acquired by Sanofi for $2.5 billion, and Personal Capital, acquired by Empower for $875 million​​. The firm was co-founded by David Coats and Trevor Kienzle, who continue to lead the team alongside key figures like Wesley Barrow and Grace Chui-Miller. With offices in San Francisco, San Diego, and New York City, Correlation Ventures continues to expand its influence by applying data-driven insights to support its investment strategy and portfolio growth​.

Cota Capital, founded in 2015 and based in San Francisco, is a multi-stage investment firm focusing on enterprise technology. The firm aims to support companies through both private and public investments, leveraging a strategic and operational approach to drive growth. Cota Capital invests in sectors such as AI, cloud computing, fintech, and cybersecurity, with notable portfolio companies including OpenGov and Mission Bio. Led by founder Bobby Yazdani, Cota Capital emphasizes a partnership model, working closely with portfolio companies to build long-term value. Their investment range typically covers early to growth stages, providing substantial support to innovative ventures​.

Cottonwood Technology Fund is a venture capital firm specializing in seed and early-stage investments in technology-driven businesses. With offices in Santa Fe, New Mexico, and Enschede, the Netherlands, the fund focuses on sectors such as chemistry and material sciences, photonics, robotics, medical technology, and clean energy. Their investment strategy targets hard science and deep tech startups, providing crucial support for commercialization and global scaling. Notable investments include companies like Skorpios Technologies, BayoTech, Respira Therapeutics, Infinitum Electric, and Exagen. Cottonwood is known for its hands-on approach, offering more than just financial backing by actively helping with strategy alignment, market entry, and connecting portfolio companies with potential customers and strategic partners. The firm’s team, led by Managing Director Dave Blivin and General Partner Alain le Loux, brings diverse expertise and a strong entrepreneurial mindset, making Cottonwood a valuable partner for startups in their portfolio.

Coughdrop Capital is an early-stage venture capital firm founded by brothers Stu and Austin Smith in 2015. Based in Bend, Oregon, with a presence in San Francisco and Los Angeles, the firm typically invests $25-50K in pre-seed and seed-stage startups across various sectors. Their investment philosophy centers on backing smart, ambitious founders regardless of the industry​. The firm has a diverse portfolio that includes notable investments in companies such as Superhuman, Lattice, Mercury, Ware, Dreamship, Ever Loved, Housable, Fast, and Catch. Coughdrop Capital is known for its founder-friendly approach, often providing strategic guidance, valuable introductions, and operational support to its portfolio companies​. Stu Smith brings extensive experience from his roles at WarnerMedia and Teespring, focusing on driving innovation in the entertainment and media sectors. Austin Petersmith, on the other hand, is the founder and CEO of Capiche, a platform for honest conversations about SaaS, and has a background in growth and marketing roles at early-stage startups​. Coughdrop Capital's investment strategy emphasizes quick decision-making and maintaining a supportive relationship with founders. They have been praised for their helpfulness, integrity, and ability to stay out of the way when not needed, while being available to offer support and resources when required.

Counteract is a London-based venture capital fund dedicated to advancing carbon removal technologies. Launched with its inaugural fund, Counteract One, the firm is committed to catalyzing large-scale CO2 removal by investing in early-stage companies across a variety of carbon removal methods. The fund’s goal is ambitious: to enable the removal of 5 gigatonnes (Gt) of CO2 by 2050. Counteract targets a broad range of carbon removal solutions, including direct air capture, bioenergy, mineralization, and natural climate solutions such as forestry and regenerative agriculture. The firm invests globally, focusing on pre-seed and seed-stage companies with the potential to scale and make a substantial impact on the carbon removal industry. Counteract typically writes first checks ranging from $250K to $1M, seeking to back companies that meet its strict criteria of scalability, sustainability, and the ability to generate a viable long-term business model. The portfolio includes innovative startups like Vesta, RepAir, and Agricarbon, all of which focus on groundbreaking technologies designed to capture or sequester CO2. Counteract’s investment strategy is driven by a deep understanding of the carbon removal ecosystem, and the firm emphasizes the need for global collaboration to meet climate goals. With support from major investors like Equinor Ventures and Anglo American, the firm is positioned as a leader in the carbon removal space, aiming to foster innovations that will help mitigate the global climate crisis.

Counterfactual Ventures is a London-based venture studio and investment fund founded in 2020, focused exclusively on replacing factory farming with more humane, sustainable, equitable, and nutritious alternatives. The firm operates at the intersection of venture capital, incubation, R&D, and talent sourcing — combining $300,000 in pre-seed capital with six months of tailored incubation support for each company it backs. This integrated studio model reflects a conviction that the alternative protein space requires purpose-built founding support, not simply funding. The firm is listed on Climatebase and Vevolution, reflecting its deep sustainability and animal welfare mission. Counterfactual has made approximately 10 investments across food and beverage technology, biotech, and sustainability. The firm leads its rounds at the pre-seed stage. Its team of roughly six professionals brings backgrounds from Founder's Factory, Entrepreneur First, Intellectual Ventures, NASA, L'Oréal, and Cambridge University, reflecting a deliberately interdisciplinary approach to identifying and scaling alternative protein opportunities. The firm works with institutional partners, research collaborators, and leaders across the alternative protein industry to uncover the most strategically important opportunities and design high-potential technical and commercial solutions. By operating as studio, fund, and R&D institute simultaneously, Counterfactual aims to build profitable startups from first principles — applying rigorous technical and commercial analysis to a sector that the firm believes represents one of the most consequential transformation opportunities in the global food system.

Courtyard Ventures is an early-stage venture capital firm based in Berkeley, California, focused on investing in startups that emerge from the UC Berkeley ecosystem. Founded in 2021, the firm supports student and alumni-led ventures, leveraging its connection to UC Berkeley’s innovative network. Courtyard Ventures specializes in sectors like business software, education technology, and logistics, aiming to fuel startups with high growth potential. The fund has backed companies like Ruuf, a platform in the information services space, and EdVisorly, an education-focused startup. Courtyard typically invests at the seed stage, providing early funding and strategic support to help startups navigate the complexities of scaling their businesses. Led by partners such as Dogakan Toka and Kevin Chang, Courtyard Ventures focuses on nurturing founders through its extensive network, especially within the Haas MBA program and other Berkeley alumni connections. With an eye on building category-leading companies, Courtyard Ventures is well-positioned to drive innovation from the university's entrepreneurial ecosystem.

Covalent Ventures is a globally connected food and health impact investor founded in 2021 and headquartered in Auckland, New Zealand, with additional presence in Switzerland. The firm focuses on Series A health and wellness investments, actively working with portfolio companies to scale into major global markets across the Asia-Pacific region, Switzerland, and the United States. Partner Kelvin Keh brings more than 20 years of international healthcare experience spanning biotech and pharma, medical devices, digital health, nutrition, and consumer packaged goods. The combined investment team holds 50 or more years of sector experience and a track record of at least 17x growth. Covalent deploys checks of $500,000 to $4 million per company with a sweet spot of $2 million, investing across seed through Series B stages in 11 portfolio companies. Sector coverage spans food systems, nutrition science, biotech, pharmaceutical, medical devices, digital health, healthcare systems, novel ingredients, and cell and gene therapy — a deliberately broad mandate within the health and food impact thesis. The firm's investment philosophy holds that human health is inseparable from food systems, and that the most consequential companies in this space bridge both domains. Covalent works alongside founders to access green and brownfield markets — new categories as well as established markets ripe for disruption — bringing sector expertise and a global network to bear on the commercial challenges that health and food technology companies face as they scale from early traction to institutional scale.

Covenant Venture Capital is a New York-based firm focused on high-potential, growth-stage companies, particularly in technology sectors like AI, aerospace, and enterprise applications. Founded in 2020, Covenant's portfolio features notable investments in companies such as Anduril, a defense technology leader, and Zipline, a pioneer in drone delivery services. Covenant has a reputation for supporting unicorns, with Anduril and Zipline both achieving billion-dollar valuations. Covenant takes a strategic approach, balancing high-reward investments with risk management, often structuring credit investments to complement their equity portfolio. They have raised multiple funds and are known for their strong ties with institutional investors, including pension funds and endowments. Led by a small team of four partners, Covenant places a strong emphasis on working closely with its portfolio companies, providing not only capital but also strategic guidance to help them scale. They primarily invest in the U.S., though their portfolio also includes international ventures, demonstrating their global outlook.

Co-Win Ventures, founded in 2009 and based in Beijing, China, is a prominent early-stage investment firm focusing on the Technology, Media, and Telecommunications (TMT) and healthcare sectors. Their portfolio features a variety of innovative companies, including KBP Biosciences, Celsius Therapeutics, Thrive Earlier Detection, and Fluent BioSciences. The firm supports both early-stage and growth-stage companies, providing capital and strategic guidance to help them scale successfully. Co-Win Ventures has a strong presence in both China and the USA, leveraging its extensive network to foster innovation and growth. Their investment approach combines financial backing with hands-on support, ensuring that their portfolio companies have the resources they need to thrive in competitive markets. By focusing on sectors with high growth potential, Co-Win Ventures aims to drive advancements in technology and healthcare, contributing to significant industry developments. Their commitment to supporting visionary entrepreneurs has made them a key player in the venture capital landscape.

Coyote Ventures is a venture capital firm focused on early-stage investments in women’s health and wellness startups. Founded in 2021 by Jessica Karr, the firm aims to address the significant underinvestment in women’s health, a market estimated to exceed $1 trillion globally. Coyote Ventures backs innovative consumer and digital health companies, particularly those solving problems that disproportionately affect women and underserved populations. With a portfolio that includes companies like Wile (hormonal wellness), Hera Biotech (endometriosis diagnostics), and Flex (cycle care), Coyote Ventures is building a synergistic pipeline in the rapidly growing femtech sector. The firm’s investment strategy prioritizes founders with deep expertise and lived experience, ensuring solutions are both impactful and practical. Additionally, all of the portfolio companies have female CEOs, with many co-founders being BIPOC or LGBTQ+. Coyote Ventures’ inaugural fund has attracted backing from prominent investors, including Bank of America, The Case for Her, and Tripple Family Office, solidifying its position as a key player in the health and wellness investment space. By championing women-led innovations, Coyote Ventures aims to drive systemic change in how healthcare is designed and delivered for women.

CP Ventures is a Sydney-based venture capital fund founded in 2018 that backs the world's best companies in their niche — highly scalable, breakthrough technology startups operating at the frontier of their categories. The fund manages approximately $14 million in assets and is led by a team of 10, including three partners, who have collectively made more than 100 personal angel and fund investments globally. The firm invests primarily at pre-seed and seed stages with checks ranging from $100,000 to $500,000, with a portfolio of 38 companies concentrated in Australian startups but extending globally. CP Ventures deploys capital across AI, healthtech, fintech, biotechnology, SaaS, and B2B services, with geographic reach spanning Australia, the United States, New Zealand, India, Singapore, Hong Kong, Colombia, and Brazil. The fund does not lead rounds but participates as a high-conviction early supporter, positioning alongside founders who are building businesses with the potential to dominate their specific niche rather than competing across broad horizontal markets. The firm's stated mission is to be the fund of choice for world-changing startups and the investors who want to empower them, combining skilled people, a collaborative culture, and what it describes as pioneering processes and technology. This early-stage, globally distributed approach reflects a conviction that breakthrough technology companies emerge across multiple geographies and that access to early Australian and Asia-Pacific founders — before they have significant US investor coverage — creates a structural sourcing advantage.

CPT Capital, based in London, is the venture capital arm of a leading private family office. The firm specializes in investing in companies revolutionizing the food and materials technology sectors, particularly in the realm of alternative proteins. CPT Capital's mission is to drive this revolution by partnering with visionary founders and supporting them from pre-seed stages through to IPO or sale. As a long-standing investor in the alternative protein space, CPT Capital focuses on plant-based proteins, biomass fermentation, recombinant proteins, and cultivated meat. Their portfolio includes groundbreaking companies like Impossible Foods, Beyond Meat, and Upside Foods, all of which are at the forefront of developing sustainable and innovative food solutions. CPT Capital seeks companies with products that directly replace animal-derived products and possess a strong technological or intellectual property component. The firm is geographically diverse, with investments spanning the US, Israel, Europe, the UK, and Asia. The firm is dedicated to addressing global challenges related to food production and sustainability, aiming to replace traditional animal protein sources with more sustainable alternatives. This approach not only promises environmental benefits but also aims to improve public health and resource efficiency.

Craft Ventures is a venture capital firm that focuses on early-stage investments in B2B software, marketplaces, and transaction-based business models. Established in 2017, Craft Ventures is led by a team of seasoned entrepreneurs and investors, including Jeff Fluhr, co-founder of StubHub, and David Sacks, former COO of PayPal. Craft Ventures' strategy includes providing more than just capital. They offer strategic support to portfolio companies, helping them build robust go-to-market strategies, optimize operations, and scale effectively. Their team comprises individuals with extensive experience in marketing, growth, and operations from successful tech startups like ClickUp and Callin. With a presence in San Francisco and a commitment to working closely with founders, Craft Ventures aims to identify and support the next generation of category-defining companies.

CRCM Ventures is a venture capital firm founded in 2004, headquartered in San Francisco, with a focus on early-stage investments in both the US and Greater China. The firm targets sectors such as healthcare and wellness, fintech, blockchain technology, media, and frontier technology. CRCM Ventures has an impressive portfolio, including three unicorns: Apollo, Blockdaemon, and Iterable. Notable public companies in their portfolio include Ginkgo Bioworks, which went public on the NYSE in 2021, and Yiju Enterprise Group, listed on the Hong Kong Stock Exchange. Additionally, CRCM has seen multiple acquisitions, such as The Drone Racing League and Spin, reflecting their success in identifying and supporting high-potential startups. The firm is led by a team of experienced professionals, including Chun Ding, who is based in San Francisco. Their investment strategy emphasizes backing innovative technology-driven companies with the potential to transform industries. CRCM Ventures combines a strong presence in Silicon Valley with deep connections in China, leveraging their dual-market expertise to drive growth and innovation in their portfolio companies. This approach allows them to provide significant value to startups looking to expand and scale their operations globally.

Creadev, established in 2002 and supported by the Mulliez family, is a global evergreen investment firm dedicated to nurturing companies that have the potential to become industry leaders. With a presence in Paris, Shanghai, New York, and Nairobi, Creadev has built a diverse portfolio across healthcare, sustainable consumption, and food sectors. One of their notable investments is Twiga Foods, a prominent food distribution platform in Kenya that uses technology to streamline the supply chain between farmers and vendors, enhancing efficiency and sustainability. Another significant investment is Victory Farms, an East African aquaculture platform addressing nutritional security through sustainable fish farming solutions. Creadev has also backed Everytable, a U.S.-based food and beverage company committed to providing affordable and healthy meals to underserved communities. In the realm of plant-based foods, Creadev has invested in The Jackfruit Company, which produces meat substitutes using jackfruit, catering to the growing demand for sustainable and healthy food options. Additionally, they support Lifen, a French health tech company offering digital solutions to improve healthcare delivery and patient management. Creadev's investment approach emphasizes long-term commitment and aligns the investment horizon with the entrepreneurial vision. They often lead funding rounds and work collaboratively with other investors to support the growth and expansion of their portfolio companies. This strategy reflects their dedication to fostering sustainable and impactful businesses globally​.

Creandum is a leading European venture capital firm that specializes in early-stage investments, focusing on technology-driven companies within the consumer, software, and hardware industries. Founded in 2003, Creandum operates from its hubs in Stockholm, Berlin, London, and San Francisco, and is renowned for its thesis-driven approach to investing. The firm's notable portfolio includes high-profile companies such as Spotify, Klarna, Bolt, Depop, and Kahoot!. Creandum has also recently raised its seventh fund, a €500 million vehicle dedicated to supporting seed and early-stage startups across Europe. This fund aims to continue backing innovative companies poised to become global leaders. Creandum's investment philosophy emphasizes long-term commitment to founders, supporting them through the various stages of their growth journey. The firm prides itself on its deep industry expertise and extensive network, which it leverages to help startups scale and succeed in competitive markets. Recent investments include companies like Prewave, a supply chain disruption solution, and Plancraft, a platform digitizing work processes in the craft industry.

Creative Ventures is a venture capital firm focusing on market-driven deep technology investments. They invest in early-stage B2B companies that are commercializing novel scientific and engineering innovations. Key investment sectors include climate change adaptation and mitigation, healthcare, and addressing labor shortages in industrial and service sectors. The firm prides itself on a market-first approach, ensuring that the technologies they invest in are primed to meet existing market demand rather than speculative future needs. This strategy helps mitigate risks associated with deep tech investments​ (Creative Ventures)​​ (Creative Ventures)​. Creative Ventures has been a lead or co-lead investor in 80% of their investments from the current fund, often being the first institutional investor on a company's cap table​. Notable portfolio companies include Path Robotics, Sepion Technologies, and OncoPrecision, which focus on autonomous welding robots, advanced materials for energy storage, and oncology drug efficacy, respectively​. The team, led by General Partners Alex Luce and Kulika Weizman, brings extensive expertise in areas such as material science, synthetic biology, and biotechnology.

Creator Fund is a venture capital firm focused on backing scientific founders at the pre-seed and seed stages, primarily across the UK and Europe. Founded in 2019 by Jamie Macfarlane, the fund specializes in investing in deep technology and life sciences startups that emerge from university research. With a unique model, Creator Fund operates a network of PhD students across 25+ leading European universities, helping to identify promising ventures at the earliest stages of development. Creator Fund typically invests between £100,000 to £700,000 in early-stage startups, often backing companies where at least one founder is an academic—whether a professor, PhD, or recent graduate. They have built a diverse portfolio, including companies like Baseimmune (biotechnology) and Recycleye (AI-driven waste management). Their sector focus spans deep tech areas such as artificial intelligence, robotics, quantum computing, and biotech, aiming to support founders who are pioneering breakthroughs in their fields. Their investment strategy also emphasizes long-term involvement, often supporting founders through multiple funding rounds and connecting them with a strong network of co-investors across Europe and the U.S. The fund's leadership team, alongside Macfarlane, includes seasoned professionals who bring expertise from venture capital and deep-tech industries.

Crédit Mutuel Equity, the private equity arm of Crédit Mutuel Alliance Fédérale, focuses on supporting companies at various stages of their development, from early-stage growth to transformation and international expansion. Based in France, the firm has a diverse portfolio encompassing over 350 companies globally. Key investments include UroMems, which develops implantable mechatronics technology for medical applications; Quandela, a leader in quantum photonics; and HarfangLab, a cybersecurity company specializing in endpoint detection and response. Other notable companies in their portfolio are Latitude, a space launcher operator, and MentorShow, an EdTech SaaS platform. Crédit Mutuel Equity invests across multiple sectors, including healthcare, technology, consumer goods, energy, real estate, and logistics. They typically support companies with innovative business models and substantial growth potential, providing both financial investment and strategic guidance to help them scale and succeed.

Crista Galli Ventures is a London-based evergreen venture capital fund founded in 2019, operating as the healthtech investment arm of IPQ Capital — the family office of Dr Fiona Pathiraja and Søren Fryland Møller, who serve as the fund's two partners. Also active from Copenhagen, the firm focuses on European healthtech startups led by clinicians and domain experts, investing at the nexus of biology, technology, and medicine. The evergreen structure allows the fund to maintain long-term positions and support founders through extended development timelines typical of healthcare innovation. Crista Galli invests at Seed and Series A stages, writing checks from €100,000 to £3 million, across digital health, AI-enabled clinical tools, medical devices, and personalized medicine. With 48 investments across the UK, Germany, France, Spain, and the Netherlands, the portfolio includes Bugbiome, Kanjo Health, CardiaTec, Inne, Keleya, Leda Health, and aeon — spanning fertility, cardiology, digital therapeutics, and wearable health monitoring. The firm's clinical and scientific credibility is central to its value proposition. Dr Pathiraja's background as a physician-investor enables Crista Galli to evaluate clinical validity and adoption potential in ways that purely financial investors cannot. The fund backs companies with strong user adoption potential and genuine capacity to solve real-world healthcare problems at scale.

Crosslink Capital, founded in 1989, is an early-stage venture capital firm based in Menlo Park and San Francisco. The firm focuses on investing in disruptive and market-transforming companies across enterprise and consumer technology sectors. As of April 2024, Crosslink closed its tenth flagship venture capital fund, Crosslink Ventures X, with $350 million in capital commitments, maintaining its focus on backing early-stage entrepreneurs from pre-seed through Series A stages​. A key component of Crosslink's strategy is the Alpha Network, an invite-only community of over 2,000 founders, CEOs, investors, and operators, established by General Partner Eric Chin in 2005. This network facilitates more than 40 annual events, including thematic discussions, networking parties, investor summits, and conferences, providing a rich ecosystem of support for founders. In conjunction with the recent fundraise, Crosslink has added Anduena Zhubi as the Director of Business Development, aimed at enhancing post-investment support for portfolio companies. Zhubi brings extensive industry experience from her previous roles at Microsoft and its venture arm, M12.

Crossroad Venture Capital Fund (Crossroad FCP) is a Luxembourg-based open-ended venture capital fund whose units are listed on the Luxembourg Stock Exchange, making it one of the few publicly traded early-stage venture vehicles in Europe. Founded in 2010 and backed by the Generali Insurance Group as its primary LP, the fund focuses exclusively on early-stage Israeli companies with unique intellectual property, exceptional management teams, and strong potential for market penetration and growth. Generali's permanent capital backing gives Crossroad a longer investment horizon than typical closed-end funds. The fund invests at pre-seed and seed stages, deploying $1 million to $10 million per company across medical devices, information and communications technology, renewable energy, biotechnology, and pharmaceuticals. With 15 investments spanning healthtech, AI, biotech, energy, and pharma, Crossroad covers Israel's strongest technology sectors. The fund leverages Generali's multinational network and strategic relationships to add value beyond capital — particularly in commercialization support for Israeli companies seeking to scale into European markets. Crossroad's structure as a listed, open-ended fund backed by one of Europe's largest insurance groups differentiates it meaningfully in the Israeli deep tech ecosystem. This combination of stock exchange liquidity, permanent capital, and a marquee corporate LP provides portfolio companies with a credible long-term institutional partner at the earliest stages of company development.

Crowberry Capital, a venture capital firm based in Reykjavik, Iceland, and Copenhagen, Denmark, focuses on seed and early-stage investments in the Nordic region. Founded by Helga Valfells, Hekla Arnardottir, and Jenny Ruth Hrafnsdottir, the firm aims to support innovative and high-potential startups across various sectors, including technology, digital health, and gaming. The firm has raised Iceland’s largest VC fund, a $90 million vehicle, which supports their mission to back diverse and bold entrepreneurs. Crowberry Capital’s portfolio includes notable companies such as Mainframe Industries, a gaming studio developing cloud-native social sandbox MMO Pax Dei; Lucinity, an AI-powered anti-money laundering platform; and Garden.io, which automates cloud development processes. Other investments include companies like Dreamdata, which focuses on B2B revenue attribution, and Kind, a provider of digital communication tools for healthcare providers​. Crowberry Capital prides itself on a strong follow-through philosophy, offering not only capital but also strategic support to help startups scale. Their approach has attracted significant interest from US VC funds at the Series A stage, highlighting the collaborative and robust nature of the Nordic startup ecosystem​.

CRV (formerly Charles River Ventures) is a well-established venture capital firm, founded in 1970, that focuses on early-stage investments in both enterprise and consumer technology startups. With over five decades of experience, CRV has supported the growth of more than 600 companies, including major successes like DoorDash, Airtable, Postman, and HubSpot. The firm is known for its hands-on approach and long-term commitment to helping founders build transformative companies. CRV typically leads investments and prides itself on moving quickly, often providing a term sheet within 24 hours. The firm aims to be a founder's first check, backing ambitious projects even in their earliest stages. They invest across various sectors, from enterprise software to consumer products, with notable focus areas like APIs (Postman), cloud networking (Aviatrix), and no-code solutions (Airtable). The firm’s investment ethos is built on forming deep, lasting partnerships with entrepreneurs, helping them navigate challenges and scale their businesses. CRV has offices in San Francisco and Palo Alto, California, with a team of partners experienced in working with startups through both good times and bad.

Crystal Horse Investments (CHI) is a Singapore-based venture capital firm with a focus on early-stage, angel, and seed investments. Established to support innovative startups across Southeast Asia, CHI has built a strong reputation for identifying high-potential companies, particularly in the technology, mobile, gaming, and web-based sectors. The firm actively participates in early funding rounds, including pre-seed, seed, and occasionally Series A, offering startups the critical capital and guidance they need to scale rapidly in competitive markets. Beyond just financial investment, CHI operates as an incubator, providing hands-on mentorship and strategic support to its portfolio companies. Startups benefit from Crystal Horse’s extensive network, industry insights, and operational expertise, allowing them to accelerate growth and navigate common early-stage challenges. The firm also collaborates with government initiatives such as Singapore’s iJam Reload program, which aims to nurture the next generation of tech innovators by providing incubation, mentorship, and early-stage funding opportunities. CHI has backed a diverse range of companies, from mobile app developers to cutting-edge web technology firms. With a strong belief in fostering innovation, CHI is committed to supporting entrepreneurs who are building the future of Southeast Asia’s digital economy. Their flexible investment approach, coupled with deep market knowledge, makes Crystal Horse a valuable partner for startups aiming to disrupt industries and scale regionally.

Cultivation Capital is a venture capital firm focused on early-stage investing, primarily at the Seed and Series A phases, with initial investments ranging from $100,000 to $3.5 million. Founded in 2012, the firm manages a family of funds targeting sectors such as life sciences and health tech, software and IT, agriculture and food tech, and geospatial technology. The firm has a mission to advance entrepreneurs with capital, counsel, and support while exceeding investors' expectations and creating opportunities for its team through career advancement and community impact. The firm operates several specialized funds, including partnerships with entities like the Yield Lab for Food and AgTech investments, and has backed over 120 startups. Notable investments include companies in diverse sectors such as therapeutics, diagnostics, precision agriculture, and location intelligence. Cultivation Capital is committed to building an inclusive portfolio, having invested in startups across more than 25 states and countries. The leadership team includes experienced venture capitalists and industry experts like co-founders Cliff Holekamp and Brian Matthews, as well as general partners and advisors with extensive backgrounds in their respective fields. The firm emphasizes active involvement with its portfolio companies, often taking board positions to provide strategic guidance and leverage their network of partners and investors.

Cultivian Sandbox Ventures is a venture capital firm dedicated to investing in innovative startups within the food and agriculture sectors. Founded in 2008 and headquartered in Chicago, the firm focuses on technologies that enhance crop production, animal health, food safety, and sustainability​. The firm has a robust portfolio featuring companies such as Vestaron, which is leading advancements in peptide-based crop protection, Supergut, offering functional food products for gut health, and Sound Agriculture, which develops products to help plants utilize soil nutrients more effectively​​. They also back companies like Geltor, which produces animal-free protein ingredients, and Full Harvest, a B2B marketplace for surplus produce​ (Cultivian Sandbox Ventures)​. Cultivian Sandbox Ventures recently closed its third fund at $135 million, with prominent investors including Archer Daniels Midland, Corteva Agriscience, and Ecolab. This fund focuses on Series A and B deals, with a global investment scope, looking particularly at synthetic biology, AI, and advanced materials​​. The team is led by experienced professionals like Andy Ziolkowski, who has over 30 years in venture capital and merchant banking, and Dan Phillips, who emphasizes the firm's commitment to platform technologies with multiple market applications​.

Cure Kids Ventures (CKV) is a seed and early-stage venture capital fund based in Auckland, New Zealand, established in 2008 as part of Cure Kids, a leading child health research charity. CKV invests in the commercialization of innovations that have the potential to improve child health globally. The fund focuses on healthcare-related sectors, including medical devices, biotechnology, diagnostics, medications, and health information systems. Its mission aligns closely with Cure Kids’ vision of a healthier future for children, supporting solutions that can make a significant impact on pediatric care​. CKV typically invests in pre-seed, seed, and Series A rounds, with initial investments ranging from under $500,000 to $3 million. The fund is highly selective, emphasizing strong commercialization potential. CKV has built an impressive portfolio, backing companies like the a2 Milk Company, Pictor, and The Clinician, which are making waves in health tech and biotech industries. Their investments are strategically aimed at driving innovations that address critical health challenges faced by children. The team at CKV brings global experience in biotechnology and healthcare, providing not only financial backing but also valuable insights into early-stage development and commercialization. CKV has played a crucial role in fostering the growth of New Zealand’s healthcare innovation ecosystem, and its impact extends beyond capital, as it works closely with startups to help them achieve market success.

Cure Ventures, based in Boston, Massachusetts, is a life sciences venture capital firm founded in 2021. The firm focuses on early-stage investments in biotechnology, particularly in new therapeutics. They aim to drive groundbreaking curative technologies from concept to clinical success. Cure Ventures closed their inaugural fund at $350 million, indicating substantial resources dedicated to their mission. The investment strategy at Cure Ventures emphasizes genetic validation to guide drug development, thus increasing the probability of success while reducing the cost of failure. They use a seed funding model to de-risk scientific ventures, with plans to co-lead Series A and B rounds for promising companies. Their hands-on approach involves embedding Cure operators within portfolio companies to assist with day-to-day decision making​. The team at Cure Ventures includes co-founders Richard Lim, David Fallace, and Lou Tartaglia, who bring extensive experience from successful biotech firms like Juno Therapeutics and Agios Therapeutics. Their backgrounds provide a strong foundation for supporting startups through scientific and operational challenges. Notable investments by Cure Ventures include Clasp Therapeutics, Kenai Therapeutics, and Tasca Therapeutics, reflecting their focus on innovative biotechnological solutions. Startups looking to approach Cure Ventures should highlight their potential for breakthrough therapies and be prepared for an intensive, collaborative partnership aimed at achieving significant medical advancements.